Auna SA Class A Ordinary Shares (AUNA)
FairStock Score: 52/100 — MIXED
Key Financials
| Current Price | $5.16 |
| Market Cap | $379M |
| P/E Ratio | 86 |
| ROE | 1.62% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At the 2026-10-13 close, Auna traded at $5.33 with a $379.2M market value. It runs hospitals and clinics in Mexico, Peru, and Colombia, plus prepaid health, dental, vision, and oncology plans and medicine sales. In fiscal Q2 2026, revenue was $1.2B and net income was $29.4M, only a 2.38% margin. That is a thin profit cushion for a business with D/E of 1.85 and an Altman Z-Score, per FairStock, of 0.26. FairStock's calculations at that close show P/E 88.83, P/B 0.74, ROE 1.62%, ROCE 5.22%, EV/EBITDA 4.91, and a Graham Number of $5.82, leaving an 8.42% margin of safety. The Piotroski F-Score is 7/9, and trailing free cash flow is $725.2M, a 191.3% FCF yield on the market cap. That cash-flow number looks extraordinary and deserves skepticism, but if real, it could support the low price. The FairStock Lynch category is none because only 0 years of filed results are available and three are needed. I see a leveraged, low-return healthcare operator with scale in three countries, but no proven durable moat. The price looks fair to slightly cheap only if cash flow is durable and debt does not overwhelm the thin profit stream.
In plain English: Auna runs hospitals and clinics in Mexico, Peru, and Colombia, and sells health plans and medicines. Sales are growing, but profits have fallen sharply, and the company carries a lot of debt. At $5.33, the stock looks closer to fair than expensive based on its assets and cash coming in, but the weak profit and heavy debt make it risky.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer